Mechanisms of cerebrovascular protection: oestrogen, inflammation and mitochondria.
Investigation of oestrogen action reveals a multitude of diverse effects. This brief review focuses on the impact of oestrogen on the vasculature, with particular emphasis on the cerebral circulation. Three major actions of oestrogen are discussed: enhancement of vasodilator capacity, suppression of vascular inflammation and increase in mitochondrial efficiency. In both humans and animals, oestrogen increases vasodilator tone, an effect dependent on a functional endothelium. Two distinct mechanisms are involved: increase in endothelial nitric oxide synthase (eNOS) mRNA and protein and phosphorylation of eNOS via the PI-3 kinase/Akt pathway. Both effects are mediated by oestrogen receptors (ER), but through two pathways, ER-mediated nuclear gene transcription and cell membrane-associated ERs respectively. Oestrogen also increases function of other endothelium-dependent vasodilators. Oestrogen suppresses vascular inflammation through an NF-κB-dependent effect. The inflammatory response has also been shown to vary significantly during the oestrous cycle of rodents. Emerging information shows that oestrogen increases mitochondrial biogenesis and decreases superoxide production. Suppression of mitochondrial superoxide production by 17β-estradiol in cerebral blood vessels is mediated by the ER-alpha receptor and not dependent on increased Mn superoxide dismutase activity. Oestrogen treatment also increases protein levels for a number of components of the electron transfer chain, as well as levels of transcription factors that regulate mitochondrial function. All of these actions of oestrogen could be important in mediating vascular protection, especially in the cerebral circulation. Furthermore, given the potential of mitochondrial DNA damage to contribute to pathophysiology and ageing, mitochondrial protective effects of oestrogen might contribute to the longer average lifespan of women.
Duckles
S P
SP
Department of Pharmacology, School of Medicine, University of California, Irvine, 92697-4625, USA. spduckle@uci.edu
Krause
D N
DN
D000818:Animals; D002560:Cerebrovascular Circulation / Q000187:drug effects / Q000502:physiology*; D004967:Estrogens / Q000378:metabolism* / Q000494:pharmacology; D005260:Female; D006801:Humans; D007249:Inflammation / Q000378:metabolism*; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism*
D004967:Estrogens
J Appl Physiol (1985). 2006 Oct;101(4):1252-61
16794020
J Cereb Blood Flow Metab. 2010 Mar;30(3):545-54
19861973
Hypertension. 2003 Nov;42(5):991-6
14581292
Am J Physiol Heart Circ Physiol. 2004 Aug;287(2):H588-94
15277199
Clin Exp Pharmacol Physiol. 2007 Aug;34(8):801-8
17600562
J Appl Physiol (1985). 2006 Jan;100(1):328-35
16357086
Endocr Rev. 2003 Jun;24(3):313-40
12788802
Am J Physiol Heart Circ Physiol. 2004 May;286(5):H2010-9
14684367
Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16468-73
17921256
Ann N Y Acad Sci. 2005 Jun;1052:43-56
16024750
Genes Dev. 2004 Feb 15;18(4):357-68
15004004
Mol Pharmacol. 2005 Jan;67(1):105-13
15496504
Eur J Pharmacol. 2003 Sep 30;478(1):35-8
14555182
Steroids. 2005 May-Jun;70(5-7):382-7
15862821
Neuroreport. 2002 Aug 7;13(11):1469-72
12167775
Ann N Y Acad Sci. 2008 Dec;1147:321-34
19076454
Am J Physiol Heart Circ Physiol. 2003 Jul;285(1):H241-50
12637362
Am J Physiol Endocrinol Metab. 2006 Aug;291(2):E261-7
16492687
Am J Physiol Heart Circ Physiol. 2007 May;292(5):H2333-40
17208996
Obstet Gynecol. 2005 Aug;106(2):219-26
16055568
J Pharmacol Exp Ther. 2008 Jun;325(3):782-90
18354059
Annu Rev Genet. 2005;39:359-407
16285865
Circ Res. 2003 Nov 28;93(11):1127-33
14592997
Am J Respir Cell Mol Biol. 2002 May;26(5):610-6
11970914
Endocr Rev. 2006 Oct;27(6):575-605
16763155
Mol Interv. 2006 Feb;6(1):26-35
16507748
Mol Pharmacol. 2005 Oct;68(4):959-65
15994367
Circ Res. 1996 Nov;79(5):1024-30
8888695
Circulation. 2004 Jan 27;109(3):433-8
14744958
J Clin Invest. 1998 Jul 1;102(1):176-83
9649571
FEBS Lett. 2003 Jul 17;547(1-3):75-9
12860389
Circulation. 2004 Sep 21;110(12):1664-9
15353495
Stroke. 1999 Oct;30(10):2186-90
10512927
J Am Coll Cardiol. 1992 Aug;20(2):452-7
1634685
J Cell Biochem. 2008 Dec 15;105(6):1342-51
18846505
J Physiol. 2009 Nov 1;587(Pt 21):5019-23
19687123
Trends Pharmacol Sci. 2007 Jun;28(6):263-70
17466385
Biochim Biophys Acta. 2009 Oct;1793(10):1540-70
19559056
Pflugers Arch. 2010 May;459(6):841-51
20213497
Pharmacol Rev. 2008 Jun;60(2):210-41
18579753
J Appl Physiol (1985). 2001 Nov;91(5):2391-9; discussion 2389-90
11641386
Lancet. 2005 Apr 16-22;365(9468):1415-28
15836891
Mol Endocrinol. 2008 Mar;22(3):609-22
18048642
Am J Physiol. 1998 Jul;275(1):H292-300
9688926
Am J Physiol. 1998 Nov;275(5):R1571-7
9791075
Trends Mol Med. 2002 Jan;8(1):38-44
11796265
Stroke. 2002 Feb;33(2):600-5
11823676